Reported positive (2)
- ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer
Other · Moderate evidence · Feb 2026 - Rucaparib Approved for Ovarian Cancer
Other · Limited evidence · Feb 2017
Rucaparib
Get cited updates on Rucaparib
A monthly email when the research changes — $10/mo. Manage follows
Follow Rucaparib
Evidence at a glanceHuman trial / meta-analysisMixed results⚠ Studies disagree
5 published studies tagged to this agent2 human studies approved & graded (trial, observational, or meta-analysis)
Why this grade?
Human trial / meta-analysis — Includes human trial or meta-analysis evidence.
- 2 human · 0 animal · 0 lab · 3 review/other
- Most authoritative study: ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer
- Studies disagree on the reported direction (conflict flagged).
- Findings conflict across studies
- Effect sizes reported in only 1 of 5 studies
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedrucaparib
Educational only, not medical advice. OncoForge makes no claim that Rucaparib treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
Where the evidence is
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
CancerHuman evidenceMechanismSafetyTrial
Ovarian Cancer23—1
- Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis Meta-analysisMixed results
- ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer Human trialInconclusive
- Rucaparib Approved for Ovarian Cancer OtherReported positive
High Grade Epithelial Ovarian Cancer12—2
- Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer ReviewInconclusive
- ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer Human trialInconclusive
Fallopian Tube Cancer11—1
Primary Peritoneal Cancer11—1
Recurrent High Grade Ovarian Carcinoma11——
Advanced Or Metastatic High Grade Epithelial Ovarian Cancer—1—1
Epithelial Ovarian Cancer—1——
Ovarian Epithelial Carcinoma—1—1
Recurrent High Frα Ovarian Cancer—1——
Reported figures
Study mix
5 published studies by what they were done in. Lab and animal findings often do not carry over to people.
2 Human3 Review/other
Reported directionReported positive2Mixed results1Inconclusive2
What supports this page
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Guideline0
Meta-analysis1
Systematic review0
Randomized trial0
Clinical trial1
Observational0
Case report0
Review1
Preclinical0
Other2
5 studies2 human3 review/other
Tracking 5 published studies of Rucaparib: 2 in humans, 3 reviews/other.
Reported direction across studies: 2 positive, 1 mixed, 2 inconclusive.
Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.
These counts summarize what the studies reported; they are not a measure of whether Rucaparib works.
Cancers named in these studies
ovarian cancer (3)high-grade epithelial ovarian cancer (2)epithelial ovarian cancer (1)recurrent high FRα ovarian cancer (1)recurrent high-grade ovarian carcinoma (1)advanced or metastatic high-grade epithelial ovarian cancer (1)ovarian epithelial carcinoma (1)fallopian tube cancer (1)primary peritoneal cancer (1)
Conflicting evidence
Negative or mixed (1)
- Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis
Meta-analysis · Moderate evidence · Sep 2024
All studies
OtherReported positiveModerate evidenceTier 4 · clinical
ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer
ESMO open · Feb 2026 · practice_guideline
This is an Express Update to the ESMO clinical practice guideline prompted by approval of rucaparib and MIRV. The update adds rucaparib as a first-line PARP inhibitor maintenance option for epithelial ovarian cancer and recommends MIRV for recurrent, high FRα ovarian cancer after 1–3 prior therapies with a platinum-free interval under 6 months. Updated treatment algorithms to support personalised therapy are also noted.
Key findings
- This Express Update has been issued in response to the approval of rucaparib and MIRV.
- It includes rucaparib as a first-line PARPi maintenance option in EOC.
- MIRV is recommended for recurrent, high FRα ovarian cancer after 1-3 prior therapies and platinum-free interval of <6 months.
- Updated treatment algorithms support personalised therapy in newly diagnosed and recurrent EOC.
Limitations: Abstract is an Express Update and provides no primary data, numerical outcomes, or details of the evidence reviewed.; No dosing, safety, or comparative efficacy data are reported in the abstract.; Short abstract format limits assessment of the strength and scope of recommendations..
AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Meta-analysisMixed resultsModerate evidenceTier 4 · clinical
Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis
Taiwanese journal of obstetrics & gynecology · Sep 2024 · systematic review and meta-analysis
This systematic review and meta-analysis pooled seven studies of rucaparib in patients with recurrent high-grade ovarian carcinoma. The pooled objective response rate (ORR) was 0.331 (95% CI 0.221–0.449) with high between-study heterogeneity (I2 = 92.4%), and the authors report improvements in PFS and OS versus controls. Safety signals were substantial: 98.7% experienced any treatment-emergent adverse event and 61% had grade ≥3 events; common AEs and hematologic abnormalities were reported.
Reported effects: number_of_articles 7 · ORR 0.331 [0.221–0.449] · +10 more
Key findings
- The meta-analysis of seven articles revealed a pooled objective response rate (ORR) of 0.331 (95% CI, 0.221-0.449; I2=92.4%), particularly evident in the BRCA-mutated cohort.
- Rucaparib consistently outperformed controls in progression-free survival (PFS) and overall survival (OS).
- Safety evaluations indicated that 98.7% of patients experienced treatment-emergent adverse events (TEAEs), with 61% being grade 65;3.
- Notable TEAEs included nausea (69.0%), fatigue (66.8%), vomiting (37.3%), and constipation (32.1%).
- Hematological concerns comprised anemia (47.9%), thrombocytopenia, elevated AST/ALT (37.3%), and serum creatinine levels (19.7%).
- The authors note that the rucaparib group recorded higher event rates across various metrics than controls and recommend careful monitoring and dose adjustments.
Limitations: High between-study heterogeneity (I2 = 92.4%) reported for the pooled ORR.; Pooled estimate derived from seven articles only, which may limit generalizability.; Abstract reports no numeric effect sizes (HRs/CIs) for PFS or OS despite stating improvements versus controls.; High rates of treatment-emergent adverse events and grade 65;3 events raise tolerability concerns affecting applicability..
AI summary of the abstract, published automatically under the strong-evidence tier · Jul 2026; an editor has not yet reviewed it. Describes what this study reported, not medical advice. View on PubMed
ReviewTrialInconclusiveLimited evidenceTier 4 · clinicaln = 11
Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer
Revista colombiana de obstetricia y ginecologia · Jun 2024 · expert consensus / practice guideline based on literature review
BevacizumabAnastrozoleCisplatinGemcitabineTopotecanOlaparibNiraparibCarboplatinLiposomal-doxorubicinPaclitaxelTamoxifenRucaparibadvanced or metastatic high-grade epithelial ovarian cancerhigh-grade epithelial ovarian cancerovarian epithelial carcinoma
This paper is an expert consensus, not a clinical study of a single drug. Eleven specialists reviewed the literature and issued recommendations for managing advanced or metastatic high-grade epithelial ovarian cancer, including surgery, chemotherapy, genetic testing, bevacizumab, and PARP inhibitors. It does not report new patient outcomes from a trial. The document mainly summarizes what the panel suggested based on existing guidelines and evidence.
Studied with: platinum-based chemotherapy, bevacizumab, paclitaxel, carboplatin.
Key findings
- The panel suggested primary cytoreductive surgery as the initial approach when complete resection is feasible.
- Neoadjuvant chemotherapy followed by interval surgery was suggested when complete cytoreduction is unlikely or the patient has poor functional status/comorbidities.
- Bevacizumab was suggested with platinum-based chemotherapy for high-risk disease, with maintenance only if it was part of first-line therapy.
- PARP inhibitors (olaparib, niraparib, rucaparib) were suggested as maintenance in selected BRCA/HRD-defined groups.
- For platinum-resistant relapse, sequential non-platinum single-agent chemotherapy and best supportive care for poor performance status were suggested.
Limitations: This is a consensus statement/practice guideline, not an original comparative trial.; No new efficacy or safety data are reported in the abstract.; Recommendations are based on literature review and expert agreement, so they are subject to guideline-selection and expert-opinion bias.; The abstract does not provide patient-level outcomes, follow-up, or effect estimates.; Several recommendations are conditional/suggested rather than based on direct evidence from this paper..
Provides management recommendations for advanced/metastatic epithelial ovarian cancer, including several anticancer agents and maintenance strategies.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialInconclusiveLimited evidenceTier 4 · clinicaln = 1000
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · Dec 2021 · Randomized, double-blind, phase III, international, multicenter; two independent comparisons (ATHENA-MONO and ATHENA-COMBO) with 4:4:1:1 randomization
RucaparibNivolumabovarian cancerfallopian tube cancerprimary peritoneal cancerhigh-grade epithelial ovarian cancer
This report describes ATHENA, a randomized, double-blind phase III trial testing rucaparib as frontline maintenance versus placebo (ATHENA-MONO) and rucaparib plus nivolumab versus rucaparib alone (ATHENA-COMBO) in women with newly diagnosed ovarian, fallopian tube, or peritoneal cancer who responded to platinum-based chemotherapy. About 1000 patients were randomized into four arms (rucaparib+nivolumab; rucaparib+placebo; placebo+nivolumab; placebo+placebo); the primary endpoint is investigator-assessed progression-free survival. The trial completed accrual in 2020 and primary results for ATHENA-MONO were anticipated in early 2022; no outcome data are reported in this abstract.
Studied with: nivolumab.
Key findings
- Primary objectives: assess rucaparib monotherapy versus placebo (ATHENA-MONO) and rucaparib+nivolumab versus rucaparib alone (ATHENA-COMBO) as frontline maintenance after response to platinum-based chemotherapy.
- Design: international, randomized, double-blind phase III trial with two independent comparisons sharing a common arm; patients randomized 4:4:1:1 to arms A–D.
- Dosing: rucaparib starting dose 600 mg orally twice daily; nivolumab 480 mg IV every 4 weeks.
- Primary endpoint: investigator-assessed progression-free survival per RECIST v1.1.
- Sample size and status: approximately 1000 patients enrolled and randomized; accrual completed in 2020; ATHENA-MONO primary results anticipated in early 2022, ATHENA-COMBO to mature later.
Limitations: Abstract reports trial design and enrollment only; no efficacy or safety results are provided.; Primary endpoint is investigator-assessed PFS (no mention of blinded central review in abstract).; Population limited to patients who achieved response to initial cytoreductive surgery and platinum-based chemotherapy; results may not generalize to all ovarian cancer patients.; Although comparisons are independently powered, ATHENA-MONO and ATHENA-COMBO share a common treatment arm, which may have analytic implications (not detailed in abstract)..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
OtherReported positiveLimited evidenceTier 4 · clinical
Rucaparib Approved for Ovarian Cancer
Cancer discovery · Feb 2017
Rucaparibovarian cancer
The FDA approved the PARP inhibitor rucaparib for women with advanced ovarian cancer who have BRCA1 or BRCA2 mutations and who have received at least two prior chemotherapy regimens. The approval also covered the FoundationFocus CDxBRCA test as a companion diagnostic to detect BRCA alterations. The abstract provides the indication and companion diagnostic approval but does not present clinical trial data, dosing, or safety details.
Key findings
- FDA approved rucaparib for women with advanced ovarian cancer with a BRCA1 or BRCA2 mutation after at least two prior chemotherapies.
- FDA approved the FoundationFocus CDxBRCA test as a companion diagnostic to detect BRCA alterations.
Limitations: Abstract is a regulatory/approval announcement and does not present original trial data, efficacy outcomes, or safety/adverse event data.; No sample size, dosing, comparator, or follow-up duration reported in the abstract.; Cannot assess magnitude of benefit or harms from this abstract alone..
AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed
What changed recently
The latest additions to Rucaparib's evidence base, and anything that's been retracted.
Recently added- Rucaparib Approved for Ovarian Cancer Other · added Sep 2026
- ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer Other · added Sep 2026
- ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer Human trial · added Jul 2026
- Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis Meta-analysis · added Jul 2026
- Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer Review · added Jun 2026
Cancers where Rucaparib reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Preclinical only: lab / animal (3)
Epithelial ovarian cancer1 positive
Limitations: Abstract is an Express Update and provides no primary data, numerical outcomes, or details of the evidence reviewed.; No dosing, safety, or comparative efficacy data are reported in the abstract.; Short abstract format limits assessment of the strength and scope of recommendations..
Cited positive studies (1)
Recurrent high FRα ovarian cancer1 positive
Limitations: Abstract is an Express Update and provides no primary data, numerical outcomes, or details of the evidence reviewed.; No dosing, safety, or comparative efficacy data are reported in the abstract.; Short abstract format limits assessment of the strength and scope of recommendations..
Cited positive studies (1)
Limitations: Abstract is a regulatory/approval announcement and does not present original trial data, efficacy outcomes, or safety/adverse event data.; No sample size, dosing, comparator, or follow-up duration reported in the abstract.; Cannot assess magnitude of benefit or harms from this abstract alone..
Cited positive studies (1)
- Rucaparib Approved for Ovarian Cancer Other · Feb 2017
Evidence at a glance: Rucaparib by cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Includes human trial or meta-analysis evidence.
Largest credible effect: ORR 0.331 [0.221–0.449] PMID 39266137 · response rates 0.331–98.7 across 10 studies
Most authoritative study: Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis
Findings conflict across studies · Effect sizes reported in only 1 of 3 studies.
Includes human trial or meta-analysis evidence.
Most authoritative study: Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer
No numeric effect sizes reported.
Includes human trial or meta-analysis evidence.
No numeric effect sizes reported · Based on a single study.
Primary peritoneal cancerHuman trial / meta-analysisInconclusive1 human
Includes human trial or meta-analysis evidence.
No numeric effect sizes reported · Based on a single study.
Includes human trial or meta-analysis evidence.
Largest credible effect: ORR 0.331 [0.221–0.449] PMID 39266137 · response rates 0.331–98.7 across 10 studies
Most authoritative study: Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis
Based on a single study.
No primary experimental studies yet.
Most authoritative study: Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer
No human studies yet · No numeric effect sizes reported · Based on a single study.
No primary experimental studies yet.
Most authoritative study: ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer
No human studies yet · No numeric effect sizes reported · Based on a single study.
No primary experimental studies yet.
Most authoritative study: Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer
No human studies yet · No numeric effect sizes reported · Based on a single study.
No primary experimental studies yet.
Most authoritative study: ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer
No human studies yet · No numeric effect sizes reported · Based on a single study.
Dose: as studied, not a recommendation
These are doses as studied or reported, never a recommendation. The right amount of Rucaparib depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Doses reported in studies- Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer The abstract mentions doses used in GOG-0218 and ICON7 trials, but does not specify exact doses. · Review · Jun 2024
- ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer Rucaparib 600 mg orally twice daily; nivolumab 480 mg intravenously every 4 weeks (starting doses) · Human trial · Dec 2021
Clinical trials studying Rucaparib
2 ongoing · 6 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.
Completed
- The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)Primary outcome measured: Treatment Related Overall Response RateResults on ClinicalTrials.gov →Results paper (PMID 21537039) →Results paper (PMID 19826121) →Results paper (PMID 23636398) →Results paper (PMID 24833920) →Results paper (PMID 24882554) →Results paper (PMID 21205755) →Results paper (PMID 22922531) →Results paper (PMID 28709704) →Results paper (PMID 26195695) →Results paper (PMID 15169803) →Results paper (PMID 8837607) →Results paper (PMID 29330207) →Results paper (PMID 26552419) →Results paper (PMID 29097493) →Results paper (PMID 27532025) →Results paper (PMID 25192616) →Results paper (PMID 26138335) →Results paper (PMID 28167507) →Results paper (PMID 25559473) →Results paper (PMID 26028255) →Results paper (PMID 28471727) →Results paper (PMID 12648575) →Results paper (PMID 25218906) →Results paper (PMID 29214032) →Results paper (PMID 29302014) →Results paper (PMID 27325856) →Results paper (PMID 27037982) →Results paper (PMID 28489510) →Results paper (PMID 26442214) →Results paper (PMID 25019571) →Results paper (PMID 25765070) →Results paper (PMID 20620859) →Results paper (PMID 28055103) →Results paper (PMID 24703918) →Results paper (PMID 28862931) →Results paper (PMID 28403786) →Reported effect (graded from the results paper)
- Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO StudyPrimary outcome measured: Number of Participants With Relevant Co-morbidities
- Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
- Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or EndometriumPrimary outcome measured: Proportion of Patients Who Are Progression-free at 6 Months
- ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsPrimary outcome measured: Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (Efficacy Population)
3 stopped (terminated / withdrawn / suspended)
- Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months · Terminated
- A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes · Terminated
- A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) · Terminated
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.